Mode
Text Size
Log in / Sign up
N/A N=15 Diagnostic

Presence or Absence of Blood in the GI Lumen

Upper GI Bleeding

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcome: Primary: Number of Participants With True Positive Results — 3 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
HemoPill (Device); Endoscopy (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
NYU Langone Health
Primary completion
Oct 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With True Positive Results
3
PRIMARY
Number of Participants With False Positive Results
3
PRIMARY
Count of Participants With True Negative Results
5
PRIMARY
Count of Participants With False Negative Results
2

Summary

Bleedings in the upper digestive tract are common. Usually, laboratory and clinical parameters are considered to establish a suspicion for a bleeding in the digestive tract and to estimate urgency of the situation. If these parameters suggest the presence of a bleeding in the digestive tract, endoscopies are often performed to further investigate a patient's status. The above-mentioned laboratory and clinical parameters are sometimes not specific enough to reliably identify a bleeding in the upper digestive tract. The HemoPill acute is capsule device, that has a built in sensor that detects blood in the upper digestive tract. This information is valuable for the medical personnel and complements the information that is obtained from other laboratory or clinical tests

Eligibility Criteria

Inclusion Criteria

  • Patient is scheduled for endoscopy due to suspicion of UGIB based on clinical and / or laboratory findings
  • Signed informed consent
  • Age ≥ 18 years
  • Willingness and ability to participate in the study procedure

Exclusion Criteria

  • Contraindications to the use of the HemoPill acute, such as:
  • Known gastrointestinal obstruction, stricture, fistula, or diverticula
  • Dysphagia or other swallowing disorders
  • Pregnancy
  • Incapacity to provide informed consent
  • In patients with cardiac pacemakers and other implanted medical devices
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05415124). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search